The nude mouse xenograft model seems promising for the evaluation of anticancer drugs. Xenografted human tumours generally respond to agents that are active in the clinic (Povlsen & Jacobsen, 1975 , Kopper & Steel, 1975 , Osieka et al., 1977 , Shorthouse et al., 1982 . For a few tumours it could be demonstrated that xenografts reproduced the patterns of chemotherapeutic response of their source tumours (Giovanella et al., 1978 , Nowak et al., 1978 , Fujita et al., 1980 . Furthermore, Shorthouse et al. (1980) Materials and methods Animals and tumours Female nude mice (B10.LP/Cpb, 8-10 weeks old) were obtained from the Centraal Proefdierenbedrijf TNO (Zeist, the Netherlands). The mice were maintained under SPF conditions. Cages, bedding, food and acidified water were autoclaved before use. Only head and neck tumours from previously untreated patients were selected for implantation. Tumour material was dissected in slices measuring 3 x 3 x 1 mm and implanted s.c. in the lateral thoracic region on both sides of the animal. Tumours growing in nude mice were serially transplanted in a similar way. Tumour growth was measured biweekly using vernier calipers. Tumour volume was calculated as length x width x height x 0.5 (Looney et al., 1973) . Twelve lines were established in this laboratory, of which 8 were reported recently in detail (Braakhuis et al., 1983) . Two lines (HNX-J and -V) were described by Lindenberger (1981) . Lactate dehydrogenase (LDH) isoenzyme analysis of the xenografts showed that >80% of the LDH in the tumour was of human origin (Pesce et al., 1977) .
Chemotherapy
To date 14 xenograft lines were found to be suitable for chemotherapy (see Table I (Sokal & Rohlf, 1969) . Before these tests could be employed the data were checked for homoscedasticity and normality. Growth delay was defined, according to Kopper & Steel (1975) (Figure 2 ). Another reason for the choice of these high doses was that the parallel toxicity study with a daily dose for 5 consecutive days showed that tumourbearing animals appear to be less sensitive to MTX toxicity than non tumour-bearing animals (Table  II) . Using the schedule with injections on Day 1 and 8 no difference in toxicity could be found between tumour-and non tumour-bearing animals. With these high dose schedules MTX did not cause a growth delay in any xenograft line ( Figure  2) . The effects of MTX on the tumours in two patients from whom xenografts were derived were known (Table III) . Tumours of patients 
Discussion
Xenografts of head and neck cancer can be grown succesfully in athymic nude mice and used for chemotherapy studies. This study shows that, using schedules with daily injections, CDDP was an effective agent; in all 6 xenograft lines a significant growth delay was found. BLEO was also effective; in only 1/7 lines was the growth delay insignificant. Clinical experiences with these agents have shown, that BLEO and CDDP produce a partial or complete remission in 38 and 26% of patients, respectively. (Taylor, 1979) . The reason for the superiority of BLEO and CDDP against the xenografted tumours in comparison with the clinical data might be that in nude mice higher drug levels are attained. Another possibility is that only xenografts from sensitive patient tumours were tested since BLEO-and CDDP-insensitive head and neck cancer xenograft lines have been reported (Azar et al., 1982) . Although all but one of the tumour lines were sensitive to CDDP and BLEO a variation in growth delay was evident. For instance, CDDP caused complete regression of all tumours in one line and only a minimal growth delay in another. A better agreement with clinical findings could be obtained if those lines with a significant growth delay of less than two doubling times were considered insensitive in this model. It is interesting to note that MTX gave only a minimal response. Tested against 11 lines, only in one was minimal growth delay observed. Also bolus injections, which simulated the clinical situation did not result in growth delay. Partial or complete remission have been reported for MTX in 40% (Carter, 1977) to 60% (Kirkwood et al., 1981) of treated patients. It is therefore unlikely that only MTX-resistant tumours were implanted into the nude mice. Alternatively, more succesful xenograft take could have been characteristic of MTXresistant tumours. The mechanisms responsible for this resistance are perhaps important for an increased tumorgenicity in nude mice.
It is interesting that for two tumours the reaction of the xenografts to MTX did not correlate with the source tumours which were sensitive in the patient. This experience is contrary to all reported comparisons, showing similar responses of the xenografts and the source tumours to the same treatment (Giovanella et al., 1978 , Nowak et al., 1978 , Fujita et al., 1980 , Shorthouse et al., 1980 . This observed lack of correlation in the response to MTX might be attributed to a difference in pharmacokinetics of MTX between man and mouse. At least the route of administration is different. The duration of exposure of xenografts to MTX may be too short. Experiments with more frequent drug administration will be carried out to test this possibility.
Resistance mechanisms potentially induced by xenografting may also account for the ineffectiveness of MTX in this model. The intracellular content of dihydrofolate reductase, the target enzyme to which MTX binds reversibly, may be increased or the rate of MTX uptake into the tumour cell may be decreased (Chabner, 1980) . Another possibility is a reversal of MTX toxicity by exogenous purine and pyrimidine metabolites, released by a population of dying tumour cells. This cell loss could be higher in the xenografts than in the patient's tumour; a substantial part of the xenograft is often necrotic. This rescue mechanism can also be the basis of the protection against MTX toxicity by the presence of a tumour, as has been shown in the toxicity studies. With the low daily doses nucleic acid metabolites can play a role in protection against MTX toxicity since tumour (L1210)-bearing mice do not need purines to reverse MTX toxicity (Straw et al., 1977) . Further studies are needed to elucidate the cause of MTX ineffectiveness.
Toxicity studies of MTX reveal that the results are difficult to interpret. Toxicity appeared to be dependent on the presence of a tumour and, moreover, an LD10 could not be determined because of large variability. The policy to give a daily dose for as long as the mice can tolerate it is an elegant solution in screening models to overcome the toxicity problem and is also economical in mice.
In conclusion, it is clear that response to CDDP and BLEO varies for the xenograft lines, as has been shown by other authors using other tumours and drugs (Bailey et al., 1980 , Houghton & Houghton, 1980 and Nowak et al. 1978 . The lack of correlation between the xenograft and patient response to MTX appears to indicate that this model has certain limitations as a screening model for anticancer agents. It has yet to be established whether pharmacokinetic differences between man and mouse or resistance mechanisms in the xenograft itself are responsible for the lack of effect of MTX. It is also necessary that more direct comparisons between xenograft and patient response with the same agent are made. 
